AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Small Business Administration’s 8(a) Business Development Program has long served as one ...

The tech industry seems to have two thoughts when it comes to where human workers fit into the AI-powered world they are creating: Either they think that all the jobs, except perhaps their own, will ...